Ceruloplasmin levels in human sera from various diseases and their correlation with patient’s age and gender

Viorica Lopez-Avila¹, William H. Robinson², Kirk Lokits³

¹Agilent Technologies, Santa Clara, CA, USA; Corresponding author: viorica_lopez-avila@agilent.com
²Stanford University, Stanford, CA, USA
³University of Cincinnati, Cincinnati, OH, USA; Present address: Midwest Research Institute, 425 Volker Blvd, Kansas City, MO, USA

Received 7 July 2009; revised 5 August 2009; accepted 7 August 2009.

ABSTRACT

Ceruloplasmin (Cp), a copper metalloprotein in human serum has been a valuable diagnostic marker in Wilson’s disease where Cp levels tend to be low while high levels in serum were associated with myocardial infarction, neoplastic and inflammatory conditions. There is no standardized reference method for Cp and current immunologic and bichromatic assays have a number of drawbacks. The method described here uses immunoaffinity chromatography to remove six of the most abundant proteins from a serum sample and high-pressure liquid chromatography (HPLC) with a size-exclusion column to separate Cp from other serum proteins and any free Cu prior to analysis of ⁶³Cu and ⁶⁵Cu by inductively-coupled plasma mass spectrometry (ICPMS). Identification of Cp is based on retention time match of the unknown protein in the serum sample with the Cp external standard and the presence of ⁶³Cu and ⁶⁵Cu at a ratio of 2.2 ± 0.1. The method accuracy, as established independently by two of the authors with a reference serum certified for Cp, is 98 to 101% and the coefficient of variation is 6.4% and 5.4%, respectively. The assay was used to analyze a total of 167 human sera for Cp from patients with myocardial infarction (MI), pulmonary embolism (PE), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), other forms of arthritis, and a set of healthy patients as normal controls (NC). Our data show that Cp concentrations tend to be higher in MI, RA, and SLE patients, higher in female as compared to male patients, and we did not observe a correlation between Cp concentration and patient’s age for the set of 70 patients for which we had gender and age information.

Keywords: Ceruloplasmin; HPLC-ICPMS; Immunoaffinity Chromatography

1. INTRODUCTION

Ceruloplasmin (Cp) is a blue alpha-2 glycoprotein with a molecular weight of 132,000 u [1]. It binds 90-95% of blood plasma copper (Cu), has 6-7 Cu ions per molecule [1] and exhibits ferroxidase activity [1,2], amine oxidase activity [1], superoxidase activity [1] as well as it is involved in Cu transport and homeostasis [1]. Hellman and Gitlin, however, reported that Cp plays no essential role in the transport and metabolism of Cu [2] and in a separate study [3] reported that analysis of Cu incorporation into apoceruloplasmin (apoCp) in vitro showed that failure is intrinsic to mutant proteins. Linder et al. [4] claim that newly absorbed dietary Cu is transported by plasma protein carriers (i.e., albumin, transcuprein, and Cp) from intestine to liver and kidney, and that Cp is involved primarily in transport of Cu from liver to other organs. Prohanska and Gybina [5] provide details on the transport process in which Cu, imported by plasma membrane protein Ctr1, binds to Cu chaperone proteins like Atox1, which then docks with ATP7B and delivers Cu to plasma Cp.

Current analytical procedures for the determination of Cp include immunoturbidimetry and nephelometry [6], in which Cp is reacted with anti-Cp antibodies to give insoluble aggregates whose absorbance is proportional to the concentration of Cp in the sample [6], radial immunodiffusion (RID) test [7], and bichromatic assay [8]. When comparing RID with immunonephelometry a significant bias was found that was in part attributed to the variation in the antisera sources used in the two methods [7]. In the case of the bichromatic method, the procedures are based on the oxidase activity of Cp on diamines such as benzidine. The bichromatic method requires special precautions (i.e., benzidine is a known
carcinogen) and purification of substrates [9], detects only Cp and not the apoCp [10], and it is not very effective since Cp does not have its own substrate [11]. The immunologic methods also have drawbacks because antisera cross-react with apoCp thus giving higher concentrations for Cp [9]. Evidence suggests that patients with Wilson’s disease may have exhibited normal serum concentrations of Cp because the immunologic assay could not distinguish between the apoCp and Cp [10]. In general, a normal person has 0.2 to 0.5 mg/mL of Cp in serum [11].

Although low serum concentration of Cp has been an important diagnostic indicator of Wilson’s disease [10], high Cp concentrations were reported in patients with macular degenerations as compared with controls (i.e., Cp concentration 0.691 ± 0.153 mg/mL vs 0.312 ± 0.064 mg/mL) by Newsome et al. [12], in patients with MI by Reunanen et al. [13], and in a variety of neoplastic and inflammatory conditions like carcinomas, leukemia, Hodgkin disease, primary biliary cirrhosis, systemic lupus erythematosus, and rheumatoid arthritis [14].

This paper describes the peer verification of a new method for the determination of Cp in human serum at biologically relevant concentrations > 0.01 mg/mL using a reference serum certified for Cp and a set of 167 human sera from several diseases. This method, which was published recently [15], uses HPLC to separate Cp from other proteins including transcuprein (molecular weight 270,000 u) and from inorganic ions, and ICPMS to detect Cu isotopes at mass-to-charge (m/z) ratios of 63 and 65, and to identify Cp from the HPLC retention time and the signal ratios of Cu isotopes $^{63}$Cu and $^{65}$Cu measured with ICPMS. To eliminate possible interference from highly abundant proteins, some of which may bind Cu to form protein-Cu complexes, the serum sample is first depleted of albumin, IgG, IgA, transferrin, haptoglobin, and anti-trypsin using immunoaffinity chromatography prior to HPLC. Quantitation of Cp in the depleted serum is performed by external standard calibration with a Cp standard.

2. EXPERIMENTAL

Materials: the standard of Cp purified from human plasma was from EMD Biosciences/Calbiochem (La Jolla, CA) in lyophilized form from 133 µL of 50 mM potassium phosphate, pH 6.8, 100 mM potassium chloride, 200 mM ε-amino-n-caproic acid and 5mM EDTA, with a purity of >95%. The 167 serum samples were as follows: 37 patients with MI, 50 with RA, 24 with SLE, 8 with PE, 16 NC, and 32 sera (identified as “other” in this paper) were from patients with different forms of arthritis: osteoarthritis, juvenile rheumatoid arthritis, reactive arthritis, inflammatory arthritis; myositis and dermatomyositis, fibromyalgia, anthralgia, ankylosing spondilitis, spinal stenosis, Sjogren, Reiter’s syndrome, connective tissue disease, scleroderma, polymyalgia rheumatica and palindromic rheumatism gout and CREST syndrome.

ERM DA470 is a human serum certified for 15 proteins including Cp [16,17] and was purchased from RTC (Laramie, WY).

Serum preparation: all human samples were collected and utilized under Institutional Review Board approved protocols and with informed consent. To summarize, blood samples were withdrawn using sterile conditions and allowed to clot at room temperature for a minimum of 10 min. Serum was separated by centrifugation for 10 min at 4000 rpm, divided among several vials to minimize freeze-thawing, and kept at -80°C until analysis.

Immunoaffinity chromatography: high-abundant protein removal from human serum was performed on a 4.6 x 100 mm immunodepletion column (Agilent Technologies) with a capacity of 40 µL of non-diluted human serum (capacity is defined as the amount of original serum that can be loaded onto the column such that 99% of the targeted high-abundant proteins are removed for at least 200 injections on a particular column). After a 5-fold dilution of serum sample with buffer A and filtration through a 0.22 µm spin filter, 150 µL of the diluted sample was injected onto the column in 100% Buffer A at a flow rate of 0.5 mL/min for 10.0 min. After collection of the flow-through fraction (2 mL), the column was washed and the bound proteins were eluted with 100% Buffer B at a flow rate of 1.0 mL/min (volume of bound protein fraction 3 mL). The immunoaffinity column was then regenerated by equilibrating it with Buffer A for 13 min bringing the total run cycle to 30.0 min. Fraction collection of flow-through proteins was time-controlled and corresponded to the UV 280 nm absorbance of the eluting proteins. The flow-through fraction was collected and kept at 4°C using the thermostatted fraction collector, was reduced to a final volume of 30 µL using spin concentrators and analyzed by HPLC-ICPMS. Bound proteins (i.e., albumin, IgG, IgA, transferrin, haptoglobin and anti-trypsin) were eluted from the immunodepletion column and selected samples were analyzed by ICPMS (data not included here). Buffer A is a phosphate buffer (pH 7.4) and buffer B is a concentrated urea buffer in water (pH 2.25).

Instrumentation: An Agilent 1100 LC system equipped with a binary pump, degasser, autosampler (300 µL loop) with thermostat, diode array detector with 6 nm flow cell, and a thermostated fraction collector was used for the immunodepletion work. Protein separation was achieved on a silica TSKGel column SW3000 (30 cm x 4.6 mm id x 4 µm particles x 250 nm pore size)
from Tosoh Bioscience (Montgomeryville, PA). All HPLC analyses were performed on an Agilent Technologies 1100 Series High Performance Liquid Chromatography system equipped with a binary pump, degasser, autosampler (100 µL loop) and diode array detector (215 nm and 280 nm). 0.1 M Tris (pH 7) was used as mobile phase at a flow rate of 0.3 mL/min. The liquid flow from the HPLC column was converted into aerosol droplets by a Micromist nebulizer with a dual pass spray chamber. 63Cu and 65Cu scan was performed on an Agilent 7500ce ICPMS system with a quadrupole mass analyzer and an Octapole Reaction System (ORS) for matrix-based interference removal. High levels of Na in the sample can cause the formation of 40Ar 23Na polyatomic species that overlap with 63Cu. Similarly, 31P based molecular species (31P 16O 16O and 31P 18O 18O) can overlap with the 63Cu and 65Cu isotopes. The ORS with He (99.99% purity) as collision gas at 3.5 mL/min was used to eliminate these interfering species and to improve signal to noise. ICPMS conditions: outer gas (Ar) flowrate 0.15 L/min; RF power 1.55kW, flowrate 15 L/min; carrier gas (Ar) flowrate 0.8 L/min; prove signal to noise. ICPMS conditions: outer gas (Ar) used to eliminate these interfering species and to im-

3. RESULTS AND DISCUSSION

3.1. Method Performance

The performance of this method (see Table 1) was established independently by two of the authors (in separate laboratories) with a reference human serum ERM DA470 that is certified for Cp at 0.205 mg/mL using identical instrumentation. This serum was reconstituted with high purity water and analyzed in triplicate in Laboratory 1 and in seven replicates over a period of two months in Laboratory 2. The results are summarized in Table 1. The agreement between the concentration of Cp in the certified serum and the reconstituted serum analyzed by this method is excellent (method accuracy is 101% in Laboratory 1 and 98.0% in Laboratory 2). The coefficient of variation (CV) for the three replicate measurements of the freshly reconstituted serum in Laboratory 1 is 5.4%. The CV of the seven replicates performed over a period of two months in Laboratory 2 is 6.4%.

Method performance data are included in Table 2. The method detection limit was established from the instrument detection limit and applies only to sample injection volumes of 5 µL; larger injection volumes would allow a lower method detection limit but such experiments were not pursued here. The method dynamic range is given as 0.01 to 5 mg/mL since this is the range of concentrations that were tested here. Although the instrument dynamic range is 9 orders of magnitude, that would involve adjustments in ICPMS operating parameters to accommodate such a wide range. Expected concentrations of Cp in human sera are in the 0.1-2 mg/mL range, therefore a 30 µL volume of the original serum is sufficient to detect Cp at 0.1 mg/mL if the final volume of the depleted serum is 30 µL. The overall CV for method reproducibility is <10% and it is shown in Table 2 for various steps in the analysis. The identification of Cp is based on retention time match of the unknown peak in the sample to the Cp standard and the presence of 63Cu and 65Cu at a ratio of 2.2 ± 0.1 [15]. In addition, we validated the Cp measurements by performing a total Cu analysis on a set of 23 depleted sera and compared those measurements with the Cp concentrations measured by HPLC-ICPMS (see Figure 1). Regression analysis gave a correlation coefficient of

Table 1. Concentration of Cp in the ERM DA 470 reference serum.

<table>
<thead>
<tr>
<th>Table 1. Concentration of Cp in the ERM DA 470 reference serum.</th>
<th>Certified value (mg/mL)</th>
<th>Conc measured in this study (mg/mL)</th>
<th>63Cu/65Cu</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERM DA 470</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reference Serum (Laboratory 1)</td>
<td>0.205 (0.011)</td>
<td>0.208 (5.4 %)</td>
<td>2.1 (3.6%)</td>
</tr>
<tr>
<td>ERM DA 470</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reference Serum (Laboratory 2)</td>
<td>0.205 (0.011)</td>
<td>0.201 (6.4%)</td>
<td>2.2 (7.3%)</td>
</tr>
</tbody>
</table>

*Uncertainty (mg/mL) – defined as half-width of the 95% confidence interval of the mean value (K factors were chosen according to the t-distribution depending on the number of labs) [12, 13].
<table>
<thead>
<tr>
<th>3. RESULTS AND DISCUSSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1. Method Performance</td>
</tr>
</tbody>
</table>
| The performance of this method (see Table 1) was established independently by two of the authors (in separate laboratories) with a reference human serum ERM DA470 that is certified for Cp at 0.205 mg/mL using identical instrumentation. This serum was reconstituted with high purity water and analyzed in triplicate in Laboratory 1 and in seven replicates over a period of two months in Laboratory 2. The results are summarized in Table 1. The agreement between the concentration of Cp in the certified serum and the reconstituted serum analyzed by this method is excellent (method accuracy is 101% in Laboratory 1 and 98.0% in Laboratory 2). The coefficient of variation (CV) for the three replicate measurements of the freshly reconstituted serum in Laboratory 1 is 5.4%. The CV of the seven replicates performed over a period of two months in Laboratory 2 is 6.4%.

Method performance data are included in Table 2. The method detection limit was established from the instrument detection limit and applies only to sample injection volumes of 5 µL; larger injection volumes would allow a lower method detection limit but such experiments were not pursued here. The method dynamic range is given as 0.01 to 5 mg/mL since this is the range of concentrations that were tested here. Although the instrument dynamic range is 9 orders of magnitude, that would involve adjustments in ICPMS operating parameters to accommodate such a wide range. Expected concentrations of Cp in human sera are in the 0.1-2 mg/mL range, therefore a 30 µL volume of the original serum is sufficient to detect Cp at 0.1 mg/mL if the final volume of the depleted serum is 30 µL. The overall CV for method reproducibility is <10% and it is shown in Table 2 for various steps in the analysis. The identification of Cp is based on retention time match of the unknown peak in the sample to the Cp standard and the ratio of 63Cu/65Cu. The average HPLC retention time for 8 consecutive injections of the Cp standard is 8.389 min with a CV of ±5.3%. The relative abundance of the 63Cu is 69.17% and 65Cu is 30.83%, thus the theoretical ratio for 63Cu/65Cu is 2.24; based on our experimental data we set the acceptance limits for 63Cu/65Cu to 2.2 ± 0.1 [15]. In addition, we validated the Cp measurements by performing a total Cu analysis on a set of 23 depleted sera and compared those measurements with the Cp concentrations measured by HPLC-ICPMS (see Figure 1). Regression analysis gave a correlation coefficient of
0.9, which confirms literature reports that most Cu in depleted serum is bound by Cp [1]. Furthermore, we verified the number of Cu atoms bound by Cp in the ERM DA470 reference serum by determining the total Cu in the depleted sample. At a Cp concentration of 0.2 mg/mL (measured in this study for the ERM DA470 serum), 6 Cu atoms per Cp molecule would correspond to a total Cu concentration of 596 ng/mL and 7 Cu atoms per Cp molecule would correspond to 695 ng/mL. Because the total Cu measured in the depleted reference serum was in the range of 618-661 ng/mL, we concluded that Cp must contain between 6 and 7 atoms per molecule, consistent with the published data for Cp [1].

As part of method validation, a Cp standard, the ERMDA470 certified serum and one of the depleted MI sera were fractionated by HPLC and the corresponding fractions containing Cp were collected manually, and were then subjected to one gel electrophoresis followed by Cp band excision, in-gel digestion, and electrospray MS of the digest to confirm the presence of Cp [15].

**Figure 1.** Total Cu vs Cp concentration for 23 serum samples (7 PE, 1 NC, 14 MI and ERM DA470).

**Figure 2.** HPLC-ICPMS chromatograms for Cp standard and depleted serum sample.

serum sample even after its depletion of the high abundant proteins whereas the ICPMS chromatograms show only the $^{63}\text{Cu}$ and $^{65}\text{Cu}$ signals at a retention time that matches that of the Cp standard and are in a ratio corresponding to 6-7 Cu atoms per Cp molecule.

3.2. Ceruloplasmin Levels in Sera from Different Diseases

Figure 3 shows the distribution of Cp concentration across several diseases, including MI, PE, RA, SLE, other forms of arthritis (i.e., osteoarthritis, juvenile rheumatoid arthritis, reactive arthritis, inflammatory arthritis) and NC sera (167 serum samples in all). Samples derived from patients experiencing MI (37 in our study) had an average Cp concentration of $0.402 \pm 0.377$ mg/mL and exhibited Cp concentrations as high as 1.64 mg/mL, while a subset of 50 RA patients and 24 SLE patients had average concentrations of $0.447 \pm 0.215$ mg/mL and $0.426 \pm 0.264$ mg/mL and exhibited elevated Cp concentrations as high as 1.23 mg/mL and 1.24 mg/mL, respectively (Figure 3). Normal Cp concentrations are in the 0.2-0.5 mg/mL range [11] and the average Cp concentration in the set of NC sera in our study (16 patients) was $0.316 \pm 0.120$ mg/mL. When comparing Cp concentrations for our MI, RA, SLE, and “other” sera with our set of NC sera, only the RA and SLE data were statistically different from the NC in a t test (i.e., $p$ values were 0.0037 and 0.0837 for RA and SLE sera, respectively). The MI data reported here show a much higher variation than our NC data, and this variation is statistically significant (F value is 9.92, $F_{crit}$ is 2.22, and $p<0.001$). Reunanen et al. [13], using serum from 104 patients with MI or stroke and 104 matched controls, concluded that high Cp concentrations in serum were significantly associated with higher incidents of MI but not of stroke.

Hantszel et al. [18] reported for RA and polymyalgia rheumatica an average Cp concentration for 23 RA patients (22 females) of $0.7 \pm 0.4$ mg/mL and for 16 polymyalgia rheumatica patients (all females) $0.5 \pm 0.1$ mg/mL. The authors suggested that clinical data, including a history of hip and shoulder muscle tenderness and lack of positive rheumatoid factor, and a normal Cp level could distinguish polymyalgia rheumatica from rheumatoid arthritis. We observed a similar trend for RA patients as compared with patients with “other” forms of arthritis. The average Cp concentrations for RA of $0.447 \pm 0.215$ mg/mL were significantly different from the average Cp concentrations for “other” diseases, which had an average Cp concentration of $0.376 \pm 0.145$ mg/mL, only when doing a one-tail test ($p$ value was 0.041). Perhaps Cp concentrations above 0.5 mg/mL would be indicative of disease severity, however characterization of larger sample sets will be necessary to substantiate this observation.

Figures 4 and 5 show Cp concentrations as a function of patient’s gender and age, respectively. Although this is a very limited sample set (70 sera from 33 RA, 5 SLE and 32 “other” arthritis patients with 49 females and 21 males) it is interesting to note that female patients exhibited slightly higher Cp concentrations (ave $\pm$ SD of $0.392 \pm 0.153$ mg/mL) than male patients ($0.319 \pm 0.123$ mg/mL) that were statistically significant at 5% significance level (48 degrees of freedom, $t_{stat}$ 2.104, $t_{crit}$ 2.011, probability for a two-tail test was 0.0410). However, when we averaged only the Cp concentrations for the 33 RA patients by gender (24 females and 9 males) we found a larger difference between the female patients and male patients ($0.417 \pm 0.158$ mg/mL vs $0.278 \pm 0.096$ mg/mL, respectively) that was statistically significant at 5% significance level (24 degrees of freedom, $t_{stat}$ 3.059 , $t_{crit}$ 2.064, probability for a two-tail test was 0.005 ). Data reported by Lyngbye and Kroll [19] for a normal population (280 patients, 149 males and 111 females) also indicate significantly higher concentrations of Cp in female patients which are known to be caused by use of oral contraceptives [20].

There does not seem to be a correlation between the Cp concentration and patient’s age across these 70 patients with RA and arthritis (Figure 5). The average Cp concentration for RA patients was $0.370 \pm 0.149$ mg/mL and $0.384 \pm 0.163$ mg/mL for $<50$ y.o. and $>50$ y.o., respectively ( $t_{stat}$ of 0.247 is less than $t_{crit}$ 2.059, $p$ for a two-tail test was 0.807, indicating that the results were not statistically different). The average Cp concentrations for “other” arthritis patients were $0.387 \pm 0.162$ mg/mL and $0.356 \pm 0.110$ mg/mL for $<50$ y.o. and $>50$ y.o., respectively ($t_{stat}$ of 0.645 is less than $t_{crit}$ 2.048, $p$ for a two-tail test was 0.524), indicating again that the
70 serum samples from 33 RA patients, 5 SLE, and 32 other diseases
M – male (21 patients)
F – female (49 patients)

Figure 4. Cp concentration as a function of patient’s gender.

Figure 5. Cp concentration as a function of patient’s age.

results were not statistically significant). Results for a normal population indicated no age variation in adults [19], however in another study Revnic [21] reported differences (p<0.05) between Cp concentrations in RA patients < 50 y.o. and >70 y.o. We have looked at Cp concentration for 22 RA patients < 50 y.o. (12 patients) and > 66.6 y.o (10 patients) and found no significant differences at p<0.05. Age related changes in human Cp concentrations were attributed to oxidative modifications, which can likely cause conformational changes around the Cu sites [22].

4. CONCLUSIONS

The method described here uses immunoaffinity chromatography and HPLC to separate Cp from the serum proteins prior to analysis by ICPMS. By removing the six most abundant proteins from serum with immunoaffinity chromatography and by using HPLC to separate Cu bound by Cp from any free Cu in the serum sample, we demonstrated that we can measure Cp in the ERM DA470 reference serum with an accuracy of 98 to 101%. The HPLC-ICPMS method was used to analyze 167 serum samples from several diseases and a set of NC for Cp. Our data for the 167 human sera show that Cp concentrations tend to be higher in MI, RA, and SLE patients. Cp concentrations were higher in female as compared to male patients, and this trend was most prominent in patients with RA. We did not observe a correlation between Cp concentration and patient’s age for the limited set of 70 patients for which we had gender and age information. Thus, measurement of Cp levels by ICPMS represents a biomarker that when combined with conventional clinical and laboratory data may provide increased diagnostic value.

5. ACKNOWLEDGEMENTS

The authors thank Toshiaki Matsuda of Agilent Tokyo Analytical Division, Tokyo, Japan, for making available an ICPMS system for performing this research, Alex Apffel of Agilent Labs, Santa Clara, CA for making available an HPLC system with fraction collection and for assistance with the immunodepletion process.

REFERENCES


**Appendix**

**List of Abbreviations:**

Cp - ceruloplasmin  
HPLC - high-pressure liquid chromatography  
ICPMS - inductively-coupled plasma mass spectrometry  
MI - myocardial infarction  
NC - normal control  
PE - pulmonary embolism  
RA - rheumatoid arthritis  
SLE - systemic lupus erythematosus  
CREST - form of systemic sclerosis  
ERM - European Reference Materials